The Unseen Victim: How Trade Wars Hurt Scientific Collaboration

While the headlines focus on the economic victims of the trade war—the companies facing tariffs and the workers whose jobs are at risk—there is a significant unseen victim: international scientific collaboration. The escalating dispute, particularly in the high-tech pharmaceutical sector, threatens to disrupt the cross-border partnerships that are vital for medical innovation.
The pharmaceutical industry is inherently global. A new drug developed by a UK-based company like GSK is often the result of research and clinical trials conducted in multiple countries, including the United States. A 100% tariff creates a massive financial barrier that discourages this kind of collaboration. It could make it prohibitively expensive to move research compounds, trial materials, and finished products between UK and US labs and facilities.
This could lead to a “decoupling” of the US and UK scientific communities. UK firms may be forced to seek new research partners in Asia or within the EU, while US institutions may find it more difficult to collaborate with their British counterparts. This would slow down the pace of discovery and ultimately harm patients in both countries.
The pressure to onshore manufacturing also has a scientific downside. While it may create US jobs, it could also lead to the concentration of research and production in one place, reducing the intellectual diversity and resilience that comes from a globalized R&D network.
The British government’s statement that the pharmaceutical sector is “critical to our economy” is true, but it is also critical to global health. The unseen tragedy of this trade dispute is that in the fight over profits and jobs, the collaborative spirit that leads to life-saving medicines could be severely wounded.